When assisting with the development of a care plan for a client with hyperthyroidism, the nurse would anticipate which treatment?

A. Converts glycogen to glucose: The process of converting glycogento glucoseis known as glycogenolysis, and it occurs in the liver. This is actually stimulated by glucagon, not insulin. Insulinworks to lower blood sugar levels by facilitating glucose uptake.

B. Stimulates the breakdown of adipose tissue: Insulinactually preventsthe breakdown of adipose tissue. It promotes fat storageby inhibiting lipolysis (fat breakdown). It is glucagonand other hormones that stimulate fat breakdown during fasting states.

C. Stimulates active transport of glucose into muscle and adipose tissue cells: The primary function of insulinis to facilitate the uptake of glucoseinto muscleand adipose tissuecells by stimulating glucose transporterson the cell membrane. This helps lower blood glucose levels.

D. Increases the breakdown of protein into amino acids: Insulinhas an anaboliceffect on protein metabolism, meaning it promotes protein synthesisand inhibits the breakdown of proteins into amino acids. Glucagonis more involved in protein catabolismduring fasting states.

A. The nurse will monitor the client's blood glucose levels four (4) times a day: This is important, but it is an intervention rather than a goal. A goal should be measurable and focused on the client's outcome, such as maintaining specific glucose levels.

B. The client will demonstrate appropriate insulin injection techniques: This is a good educational goal, but it does not directly address the immediate concern. The problem states noncompliance, implying the client knows how to inject but isn't doing it consistently.

C. The client will maintain normal kidney function with 30-ml/hr urine output: While monitoring kidney function is important in diabetes, this goal does not address the immediate risk of hyperglycemia. Urine output is not the primary indicator of hyperglycemia.

D. The client will have a blood glucose level between 60-110 mg/dl at 1600: This short-term goal is specific, measurable, and time-bound. It addresses the desired outcome of maintaining blood glucose within a normal range, which addresses hyperglycemia due to noncompliance.